Cyp asx

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved.

Cynata Therapeutics Limited. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. About the company. CYP Stock Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Revenue is forecast to grow

Cyp asx

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast MCA to manufacture cell therapy products, including mesenchymal stem cells , on a commercial scale. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other. Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech.

Add to Your Portfolio New portfolio. Enter Keyword for Search.

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets.

Cynata Therapeutics Limited. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. About the company. CYP Stock Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Revenue is forecast to grow

Cyp asx

Key events shows relevant news articles on days with large price movements. Mesoblast Ltd. MSB 7. Starpharma Holdings Ltd. SPL 3. Anteris Technologies Ltd. AVR 0. Regeneus Ltd.

Puticlubs jerez

See more updates Recent updates. Actions Add to watchlist Add to portfolio Add an alert. Trade our cash market. Morningstar Data. Show more World link World. Featured Products and Services. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Actions Add to watchlist Add to portfolio Add an alert. Any information that you receive via FT. United States.

See all ideas.

Morningstar Investment Conference for Individual Investors. Trade our cash market. Morningstar Essentials. Enter Keyword for Search. Morningstar Direct. Our Solutions. Search the FT Search. Use our equities screener to discover other potential opportunities. Actions Add to watchlist Add to portfolio Add an alert. Our Board. Price Volatility. All markets data located on FT. Make up to three selections, then save.